Concurrent chemoradiation for high-risk prostate cancer.

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Prostate cancer is a common diagnosis, with over 220,000 cases in 2015.
• Despite being treatable, prostate cancer causes significant mortality.
• High-risk patients face high recurrence rates (32-70%) after standard treatment.

Purpose of the Study:

• To review the role of concurrent chemotherapy in definitive treatment for high-risk prostate cancer.
• To explore strategies for improving cure rates in aggressive prostate cancer cases.

Main Methods:

• Review of phase I and II clinical trials on concurrent chemoradiation for prostate cancer.
• Focus on chemotherapy agents like 5-fluorouracil, estramustine phosphate, vincristine, docetaxel, and paclitaxel.
• Assessment of safety, feasibility, and maximum tolerated doses.

Main Results:

• Concurrent chemoradiation has been studied in phase I/II settings.
• Maximum tolerated doses of chemotherapy and radiation have been identified.
• Safety and feasibility of concurrent chemoradiation have been established.

Conclusions:

• Concurrent chemotherapy with radiotherapy is a promising approach for high-risk prostate cancer.
• This strategy aims to improve clinical outcomes and cure rates.
• Further research and application in definitive management are warranted.